$iBio Inc (IBIO.US)$ iBio to Present New Preclinical Data on...
iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025
iBio (NASDAQ:IBIO) will present new preclinical data on its Activin E antibody, IBIO-610, at two scientific conferences in November 2025. Cory Schwartz, Ph.D. will deliver an oral presentation at ObesityWeek on Nov 4, 2025 and a poster on Nov 5. Martin Brenner, DVM, Ph.D. will present at PEGS Europe on Nov 12, 2025. The company highlights non-human primate data suggesting fat-selective weight loss, potential support for long-term weight maintenance, and possible synergy with GLP-1 therapies.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Market Insights
Hot Topics Hot Topics
Trump's 'Taco deal' sparks market rebound : Market rebound sustainable ?
1. If tariffs pause, which sectors benefit first? 2. Trump's "threat-compromise" cycle normalizes—how to hedge across assets?
Moo Options Explorer
Apr 7 17:28
Weekly roundup: Tariff turmoil and recession fears dominate
Moo Options Explorer
Mar 31 17:01
Weekly roundup: Tariff concerns and Tesla’s rollercoaster ride